Air Voel Expands Product Line with the Latest ResMed CPAP Machines for Enhanced Sleep Therapy.Canada - November 8, 2024 — Air ...

Sleep apnoea affects many older Australians — but managing it isn’t as difficult or expensive as you might think.

The most significant challenge facing ResMed is the potential impact of GLP-1 drugs on its core CPAP device market. Eli Lilly (NYSE:LLY)'s tirzepatide, a GLP-1 medication, is expected to receive ...

William Blair sees ResMed well-positioned to capitalize on ... driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business.

On Thursday, ResMed Inc (NYSE:RMD ... driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software ...

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...

as patients become more aware of the disease and doctors use all tools to treat the disease, including ResMed’s CPAP devices.

But the central driver of the investment thesis is ResMed's market for sleep apnoea devices, particularly continuous positive airway pressure (CPAP) machines. Put bluntly, the market size is huge ...

Sleep devices giant ResMed has brushed off investor fears that transformative weight-loss drugs threaten long-term demand for its sleep apnoea devices after posting better-than-expected first ...

we estimate ResMed’s pricing to be roughly 15% higher than the remaining peer average across the automatic positive airway pressure device category and 30% higher in the CPAP category.